Iveric Bio Inc
F:O2T
Balance Sheet
Balance Sheet Decomposition
Iveric Bio Inc
Iveric Bio Inc
Balance Sheet
Iveric Bio Inc
| Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
211
|
40
|
222
|
134
|
167
|
131
|
126
|
66
|
261
|
476
|
|
| Cash Equivalents |
211
|
40
|
222
|
134
|
167
|
131
|
126
|
66
|
261
|
476
|
|
| Short-Term Investments |
0
|
424
|
75
|
155
|
0
|
0
|
0
|
144
|
120
|
171
|
|
| Total Receivables |
0
|
1
|
4
|
4
|
1
|
0
|
1
|
2
|
0
|
0
|
|
| Accounts Receivables |
0
|
1
|
4
|
4
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
7
|
9
|
6
|
3
|
3
|
2
|
2
|
5
|
6
|
16
|
|
| Total Current Assets |
217
|
473
|
307
|
296
|
172
|
133
|
129
|
217
|
387
|
663
|
|
| PP&E Net |
0
|
2
|
4
|
3
|
1
|
0
|
1
|
0
|
2
|
2
|
|
| PP&E Gross |
0
|
2
|
4
|
3
|
1
|
0
|
1
|
0
|
2
|
2
|
|
| Accumulated Depreciation |
0
|
0
|
1
|
2
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
4
|
1
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
95
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
5
|
24
|
1
|
4
|
0
|
0
|
0
|
0
|
2
|
|
| Total Assets |
218
N/A
|
480
+120%
|
429
-11%
|
300
-30%
|
176
-41%
|
137
-22%
|
130
-5%
|
217
+67%
|
389
+80%
|
667
+71%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
4
|
9
|
12
|
12
|
8
|
6
|
6
|
13
|
13
|
23
|
|
| Accrued Liabilities |
3
|
8
|
19
|
47
|
5
|
7
|
7
|
12
|
15
|
13
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
3
|
7
|
7
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
6
|
20
|
38
|
66
|
13
|
13
|
13
|
25
|
28
|
36
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
97
|
|
| Other Liabilities |
42
|
331
|
331
|
328
|
125
|
0
|
0
|
0
|
1
|
0
|
|
| Total Liabilities |
48
N/A
|
351
+632%
|
369
+5%
|
394
+7%
|
138
-65%
|
13
-90%
|
13
-2%
|
25
+94%
|
29
+14%
|
132
+358%
|
|
| Equity | |||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
183
|
300
|
406
|
599
|
485
|
422
|
481
|
565
|
680
|
865
|
|
| Additional Paid In Capital |
353
|
428
|
466
|
505
|
523
|
546
|
598
|
757
|
1 040
|
1 400
|
|
| Other Equity |
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
170
N/A
|
129
-24%
|
60
-53%
|
95
N/A
|
38
N/A
|
124
+226%
|
117
-5%
|
192
+63%
|
361
+88%
|
535
+48%
|
|
| Total Liabilities & Equity |
218
N/A
|
480
+120%
|
429
-11%
|
300
-30%
|
176
-41%
|
137
-22%
|
130
-5%
|
217
+67%
|
389
+80%
|
667
+71%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
31
|
34
|
35
|
36
|
36
|
41
|
50
|
90
|
115
|
137
|
|